bioAffinity Technologies Announces Veteran Lung Health Program Featuring Advanced Diagnostic Technologies bioAffinity Technologies $BIAF to host webinar on July 21 highlighting advanced lung cancer screening tech for veterans, featuring CyPath® Lung and partners Philips, 4DMedical. notdumbmoney.com/biaf/202606…

$BIAF bioAffinity Technologies announcing a July 21 webinar on veteran lung health screening — featuring its CyPath Lung noninvasive lung cancer detection test alongside Philips and 4DMedical. CyPath Lung uses AI and flow cytometry on patient sputum to detect early lung cancer. Published trial showed 92% sensitivity and 99% negative predictive value in high-risk patients. Veterans are the target market here given higher lung cancer incidence and PACT Act toxic exposure coverage. Webinar announcement — not a clinical or regulatory catalyst. Not financial advice.

SPONSORED Good morning! Our featured stock is $BIAF . The company name is bioAffinity Technologies, Inc. (Nasdaq: BIAF). Tuesday's Radar Tags (Nasdaq: BIAF) And Key Potential Catalysts (Low Float Past Champ) 1.) BIAF Has An Fairly Low Float (Volatility Potential May Be Explosive). Sporting a float of roughly 4.42Mn shares, according to Yahoo Financ (source- finance.yahoo.com/quote/BIAF…), volatility potential could pop up in a flash for BIAF. 2.) CyPath Lung Unit Sales Momentum Supports Growth Story. bioAffinity Technologies is building (source finance.yahoo.com/sectors/he…) strong commercial momentum as CyPath Lung unit sales reached a record monthly high in April 2026, rising nearly 300% year over year compared to April 2025 while exceeding internal expectations. The surge suggests accelerating physician adoption and broader clinical use of its noninvasive lung cancer test. Chart see the beautiful chart (Source ca.finance.yahoo.com/quote/B…). The stock hit $5 in march of this year and now holding a key area of $1.48. Ftom this price if the stock can high of March, it could be a potential big move from here! Keep an eye!👁️ DISCLAIMER (sponsored content): I am NOT a financial advisor. ANYTHING I say, write, or do is strictly for entertainment, educational, and informational purposes only. This social media communication agreed to be compensated by a third party for an awareness campaign regarding bioAffinity Technologies, Inc. (Nasdaq: BIAF). For full compensation details regarding this post, click here: shorturl.at/TSeqP

🫁 Join SAB on June 16 at 7 PM ET for: “Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath® Lung Testing.” Hear from leading experts on AI-driven, noninvasive lung cancer diagnostics. Register➡️attendee.gotowebinar.com/reg… #Pulmonology #Bronchoscopy

🎙️ CyPath® Lung Connect Episode 2 is live! Leading pulmonologists discuss pulmonary nodule management, clinical decision-making and how CyPath® Lung is being integrated into real-world clinical workflows. Tune in: bit.ly/3QAnQ8U $BIAF

There's still time to register! Hear perspectives from a medical oncologist, thoracic surgeon and interventional pulmonologist during an upcoming @SABronchoscopy webinar on CyPath® Lung. Reserve your spot: bit.ly/3PaFPSR $BIAF

🫁 Join SAB on June 16 at 7 PM ET for: “Navigating Lower Cancer-Risk Nodules in High-Risk Patients with Noninvasive CyPath® Lung Testing.” Hear from leading experts on AI-driven, noninvasive lung cancer diagnostics. Register➡️attendee.gotowebinar.com/reg… #Pulmonology #Bronchoscopy

Noninvasive testing can streamline nodule management. CyPath® Lung gives clinicians actionable results to determine which pulmonary nodules may be malignant, guiding decisions next steps in care with confidence. cypathlung.com/ $BIAF

$BIAF is officially a runner! 🚀 Record CyPath Lung sales initiation of a massive 2,000-patient study is fueling this surge. Currently consolidating at support—don't miss the next leg up to $3.50! 📈 Check bio for my WhatsApp! #BIAF #Biotech #Stocks #Trading

When every moment counts, CyPath® Lung gives clinicians timely actionable results, helping determine whether intervention is needed and supporting informed, effective patient management. cypathlung.com/ $BIAF

Knowing a nodule’s status early allows clinicians to make clear decisions. CyPath® Lung provides actionable results that continued surveillance or definitive intervention, helping ensure patients receive the right care at the right time. cypathlung.com/ $BIAF

Mark your calendars! The @SABronchoscopy will host a live webinar on CyPath® Lung’s expanding role in pulmonary, oncology and surgical practices for the detection and management of early-stage lung cancer. 📅 Tuesday, June 16, at 7 p.m. ET bwnews.pr/4ufoZ3B $BIAF

New patent for $BIAF! Mexico is granting a new patent for our use of flow cytometry for earlier lung cancer detection. The Mexican patent expands global IP protection for CyPath® Lung, our proprietary, noninvasive test for lung cancer. bwnews.pr/4tVsn3v

Decisions about pulmonary nodules are easier with early clarity. CyPath® Lung provides clinicians with actionable results, helping guide watchful waiting or intervention and supporting better patient outcomes. cypathlung.com/ $BIAF

🫁 Join Society for Advanced Bronchoscopy June 16, 7 PM ET for webinar on managing pulmonary nodules with noninvasive CyPath® Lung testing. Register now at bit.ly/3PaFPSR #LungCancer #PulmonaryNodules #EarlyDetection #CyPathLung #oncology

bioAffinity Technologies CEO Maria Zannes presented at the Veterans Research Symposium on Capitol Hill, highlighting our clinical trial validating CyPath® Lung for military and VA centers, partially funded by the John P. Murtha Cancer Center Program. Thank you @NAVREF! $BIAF

CyPath® Lung achieved record monthly unit sales in April 2026, with volume increasing nearly 300% compared to April 2025, reflecting accelerating physician adoption and expanding clinical use. Read the release: bit.ly/4twSbTd $BIAF

BIAF : bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 $BIAF if vol only

$BIAF bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

SPONSORED 🔥 Nasdaq: $BIAF — 25% INTRADAY SURGE TO $2.82 ON ASTHMA/COPD STUDY NEWS PULLBACK = AFTERNOON SHORT-SQUEEZE BREAKOUT LOADING! 💥🚀 • 📈💰 Hit fresh highs of $2.82 ( 25% on the day) after this morning’s major CyPath® Lung expansion news — volume still elevated (Source: finance.yahoo.com/quote/BIAF…) ⚡ • 👀💣 New pilot study launched with Brooke Army Medical Center to expand CyPath® Lung into asthma & COPD diagnostics — targeting massive $92B respiratory market (Source: businesswire.com/news/home/2…) 💰 • 📉🔥 Ultra-tiny float under 5M shares setting up for explosive afternoon short-squeeze on any renewed buying pressure (Source: finance.yahoo.com/quote/BIAF…) 🔥 • 🎯 Technicals screaming breakout — pullback now offers re-entry before potential run to 200-day MA at $3.61 (Source: stockcharts.com/sc3/ui/?s=BI…) 🚀 • 🧬 Building on prior momentum — Q1 units already 146% YoY with elite advisory board validation now expanding into new respiratory indications (Source: bioaffinitytech.com/bioaffin…) 🛡️ Disclaimer: tinyurl.com/y33k6vcv